TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22059194
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR (10 mg or 15 mg every 4 to 6 hours as needed)
Study: 11968154
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (0.06, 0.12, 0.25, 0.5, 1.0, 2.0 mg/kg)
Study: 11968154
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (doses above 0.06 mg/kg)
Study: 9893888
Drug: Evidence Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence Based Emergency Medicine (EBEM) practices
Study: 7923513
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration (group SC)
Study: 3072446
Drug: Anti-anginal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anginal therapy
Study: 24510005
Drug: Brilliant Blue
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brilliant Blue G (BBG) applied at 0.2 mL for 2 minutes under air conditions during ERM surgery
Study: 16202043
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT) with infrared laser (780 nm, 30 mW, 10 s, 6.3 J/cm(2))
Study: 16202043
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT)
Study: 12076869
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Study: 12076869
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Study: 2141612
Drug: Captopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (average daily dose 269 mg, range 150 to 300)
Study: 2141612
Drug: Minoxidil (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (average daily dose 20 mg, range 7.5 to 30)
Study: 11119398
Drug: MDMA (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.5 mg/kg)
Study: 25735993
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration (Study 1)
Study: 21954280
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) treatment
Study: 21954280
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contraceptive (non-OC) treatment
Study: 17143257
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with chemotherapy (paclitaxel plus carboplatin)
Study: 17143257
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with erlotinib
Study: 17143257
Drug: Other antiangiogenic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiangiogenic approaches (small‐molecule tyrosine kinase inhibitors)
Study: 1284161
Drug: GSR 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSR 100 mg
Study: 6741684
Drug: Treatment joiners
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment joiners
Study: 24493633
Drug: Daily crossword
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily crossword intervention for 4 weeks
Study: 24493633
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily gratitude diary for 4 weeks)
Study: 22471295
Drug: SLCaps (soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLCaps (soft gelatin capsules)
Study: 22471295
Drug: HPCaps (hard
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPCaps (hard gelatin capsules)
Study: 22471295
Drug: Intravenous vinflunine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinflunine
Study: 22471295
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral formulations (SLCaps and HPCaps)
Study: 16291601
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) with clopidogrel and standard fibrinolytic and aspirin
Study: 7725867
Drug: Meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.5 mg/kg with epinephrine (14 patients)
Study: 7725867
Drug: Meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.5 mg/kg without epinephrine (16 patients)
Study: 2639069
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution mouth rinse
Study: 28386788
Drug: Compression-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression-only therapy (CT)
Study: 17313717
Drug: Iron absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron absorption efficiency
Study: 15449742
Drug: Propofol (2-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2-5 mg kg(‐1) h(‐1))
Study: 9754479
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 20 mg orally (dose 1) and 10 mg (dose 2)
Study: 9754479
Drug: Hydrocodone 10
Normalized name: HYDROCODONE 10/PPA 25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 10 mg plus acetaminophen 1,000 mg orally (both doses)
Study: 8313331
Drug: DAB486IL-2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAB486IL-2 at 0.2 mg/kg daily for 5 days
Study: 8313331
Drug: DAB486IL-2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAB486IL-2 at 0.075 mg/kg and 0.115 mg/kg
Study: 3416497
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) at doses of 0.1 and 0.33 mg/kg three times daily
Study: 3416497
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) at high dose
Study: 1070466
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapy (BCG and irradiated allogeneic myeloblastic leukaemia cells)
Study: 25042729
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of grid laser and IVR
Study: 23414646
Drug: Cognitive Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Intervention Program (CIP) for 6 months, 2 hours per session, twice per week.
Study: 21195572
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg iodine/(kg of LBW)
Study: 21195572
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg iodine/(kg of LBW)
Study: 21195572
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg iodine/(kg of LBW)
Study: 21195572
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg iodine/(kg of TBW)
Study: 11843764
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG) treatment
Study: 16042771
Drug: Steroid-naïve asthmatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-naïve asthmatic children
Study: 16042771
Drug: Inhaled steroid-treated
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid-treated asthmatic children
Study: 16042771
Drug: Steroid-treated asthmatic
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-treated asthmatic children
Study: 8694167
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + Ephedrine 15 mg
Study: 8694167
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + Ephedrine 20 mg
Study: 8694167
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + Ephedrine 10 mg
Study: 6507998
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (32 mg)
Study: 6507998
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (128 mg)
Study: 20375690
Drug: Revascularization and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization and medical therapy
Study: 20375690
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone and deferred or no revascularization
Study: 20375690
Drug: Glycemic control
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycemic control with insulin‐providing or insulin‐sensitizing drugs
Study: 18036421
Drug: Olopatadine nasal
Normalized name: olopatadine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine nasal spray 0.2%
Study: 18036421
Drug: Olopatadine nasal
Normalized name: olopatadine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine nasal spray 0.4%
Study: 18036421
Drug: Olopatadine nasal
Normalized name: olopatadine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine nasal spray 0.6%
Study: 2210238
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy with absolute ethanol
Study: 25867812
Drug: MTZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ 30 mg/d for 42 days
Study: 19585653
Drug: Viramidine (VRD)
Normalized name: lidamidine
DrugBank: Taribavirin (DB06408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viramidine (VRD) 600 mg BID
Study: 19585653
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) weight-based (1000 or 1200 mg/day)
Study: 15539716
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg (Z20)
Study: 15539716
Drug: Zafirlukast 160
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 160 mg (Z160)
Study: 11815725
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone (LDT) 62.5 mg/m2
Study: 11815725
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose testosterone (CDT) 125 mg/m2
Study: 11815725
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose testosterone (MDT) 62.5 mg/m2
Study: 11815725
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone (LDT)
Study: 11815725
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose testosterone (CDT)
Study: 9431481
Drug: Acetylcholine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine or ergonovine maleate administration
Study: 6814472
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (200 mg)
Study: 3668844
Drug: Diazepam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (40 mg)
Study: 25163405
Drug: Epinastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine 0.05% ophthalmic solution
Study: 22739038
Drug: Placebo ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: 12852709
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic solution
Study: 22530938
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) program, 8 weekly sessions of 2½ hours each.
Study: 22530938
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) program
Study: 11944589
Drug: Etizolam administered
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etizolam administered after hematoma removal
Study: 3768247
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g day‐1 for 7 days)
Study: 3768247
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg day‐1 for 7 days)
Study: 28675983
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid (IVF) supplementation (50 mL/kg over 8 hours)
Study: 28675983
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) (50 mL over 8 hours)
Study: 18843118
Drug: GAD-alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (20 microg, subcutaneous injections on study days 1 and 30)
Study: 18843118
Drug: Placebo (alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (alum alone, subcutaneous injections on study days 1 and 30)
Study: 10348471
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 12.5 mg clozapine
Study: 10348471
Drug: Chronic clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic clozapine treatment (39+/‐9 mg up to 50 mg) for 15.8+/‐7.7 months
Study: 8598837
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of labor with intravenous oxytocin
Study: 8598837
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of labor with vaginal prostaglandin E2 gel
Study: 2058572
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (without fish-oil supplement)
Study: 6337322
Drug: Decongestant-antihistamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant-antihistamine combination (pseudoephedrine hydrochloride, 4 mg/kg/day and chlorpheniramine maleate, 0.35 mg/kg/day)
Study: 6337322
Drug: Decongestant-antihistamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant-antihistamine combination
Study: 22842212
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of citalopram
Study: 18001404
Drug: 10-day moxifloxacin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day moxifloxacin-based triple therapy (moxifloxacin 400 mg q.d., amoxicillin 1000 mg b.i.d., esomeprazole 20 mg b.i.d.)
Study: 18001404
Drug: 2-week quadruple
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week quadruple therapy (esomeprazole 20 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d.)
Study: 15698450
Drug: CAPD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPD with a target creatinine clearance >/=60 L/week/1.73 m(2)
Study: 15698450
Drug: Standard 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4 x 2 L continuous ambulatory peritoneal dialysis (CAPD)
Study: 7653482
Drug: Intermittent cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclic etidronate (400 mg/d for 14 days followed by calcium 500 mg/d for 76 days)
Study: 1232529
Drug: Melphalan and
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan and prednisone 0.6 mg/kg
Study: 1232529
Drug: Melphalan and
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan and prednisone 0.3 mg/kg
Study: 20373478
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tandospirone (TSP)
Study: 20373478
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam (DZP)
Study: 16536020
Drug: Oxygen-therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-therapy with helmet
Study: 30058112
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg/day
Study: 30181533
Drug: EBD combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBD combined with triamcinolone (50 mg/5 mL)
Study: 26497691
Drug: Nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarettes (8.9 mg)
Study: 26497691
Drug: Placebo cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cigarettes (1.0 mg)
Study: 10470633
Drug: Tramadol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (150 mg bolus + 250 mg infusion over 3 hours)
Study: 10470633
Drug: Meperidine (112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (112.5 mg bolus + 187.5 mg infusion over 3 hours)
Study: 30701467
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thalidomide maintenance (Group B)
Study: 30701467
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thalidomide maintenance (Group C)
Study: 28681218
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2, day 1) with paclitaxel (80 mg/m2, days 1, 8, and 15) every 21 days as neoadjuvant chemotherapy (NAC) for 3 cycles before radical hysterectomy (RH).
Study: 28681218
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus dose-dense paclitaxel (dose-dense TP) for 3 cycles before and 2 cycles after radical hysterectomy (RH).
Study: 24720402
Drug: Bixalomer (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bixalomer (1.5 g/day adjusted to a maximum of 7.5 g/day)
Study: 24720402
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (3.0 or 6.0 g/day adjusted to a maximum of 9.0 g/day)
Study: 16083710
Drug: telbivudine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine 400 mg/day
Study: 16083710
Drug: telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telbivudine 600 mg/day
Study: 16083710
Drug: Comb400 (telbivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comb400 (telbivudine 400 mg/day + lamivudine 100 mg/day)
Study: 16083710
Drug: Comb600 (telbivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comb600 (telbivudine 600 mg/day + lamivudine 100 mg/day)
Study: 18520981
Drug: Minocycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (200 mg/d)
Study: 7011293
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets (0.96 grams) of Co-trimoxazole twice a day for one day
Study: 7011293
Drug: Four tablets
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets (1.92 grams) of Co-trimoxazole as a single dose
Study: 7011293
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Co-trimoxazole twice a day for seven days
Study: 31747035
Drug: Positive valence
Normalized name: valencene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive valence system-focused cognitive behavioral therapy with inaudible high-frequency sound
Study: 31747035
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy with placebo sound
Study: 26692255
Drug: Serotonin reuptake
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin reuptake inhibitors (SRIs)
Study: 9738752
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous antibiotics followed by oral antibiotics for 5 days after surgery
Study: 2470995
Drug: Isradipine 15
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine 15 mg/day
Study: 2470995
Drug: Isradipine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (various doses: 0, 2.5, 5, 7.5, or 10 mg twice daily)
Study: 23316787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three components
Study: 23548251
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 μg per vaginally at 24 hours after mifepristone
Study: 23548251
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and misoprostol combination at 48 hours interval
Study: 16796988
Drug: Closed suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed suction drainage of the subcutaneous space
Study: 10661480
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg daily with or without betaine 4 g per day for 12 weeks, followed by 1 or 5 mg of folic acid thereafter for 40 weeks.
Study: 10661480
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment for hyperhomocysteinemia.
Study: 29465059
Drug: Glutaraldehyde-containing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaraldehyde-containing agent (GCA) application
Study: 24074810
Drug: Ketoconazole (KTCZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTCZ) with low-dose cortisol
Study: 24074810
Drug: Ketoconazole (KTCZ)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KTCZ) with high-dose cortisol
Study: 21959825
Drug: Thiazide +
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide + Losartan 50 mg/day